The WHO estimates the average medication adherence rate is 50% in developed nations, though the U.S. trails other countries in reported adherence on Medisafe.…

Johnson & Johnson

Johnson & Johnson tops its peers in the 'most-admired' department—again

Pfizer's new Inflectra biosim data puts J&J's Remicade on notice in Crohn's

What's wrong with Sanofi's dealmaking approach? To hear Actelion tell it, plenty

EMA examines key Actelion med Uptravi following 5 patient deaths in France

Diabetes drugs pop on January's TV ad spending list, but AbbVie's Humira stays at the top

Can Xarelto's trial win in artery disease help J&J keep rival Eliquis at bay?

J&J finally grabs Actelion's marketed meds for $30B, with R&D spinoff to come

Key J&J meds disappoint in Q4, triggering a top-line miss

Actelion fails key phase 3, but investors brush it off as J&J megadeal draws near